InVivo Therapeutics Holdings (FRA:04I) COGS-to-Revenue : 0.00 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is InVivo Therapeutics Holdings COGS-to-Revenue?

InVivo Therapeutics Holdings's Cost of Goods Sold for the three months ended in Sep. 2023 was €0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was €0.00 Mil.

InVivo Therapeutics Holdings's COGS to Revenue for the three months ended in Sep. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. InVivo Therapeutics Holdings's Gross Margin % for the three months ended in Sep. 2023 was N/A%.

InVivo Therapeutics Holdings COGS-to-Revenue Historical Data

The historical data trend for InVivo Therapeutics Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings COGS-to-Revenue Chart

InVivo Therapeutics Holdings Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

InVivo Therapeutics Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

InVivo Therapeutics Holdings COGS-to-Revenue Calculation

InVivo Therapeutics Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

InVivo Therapeutics Holdings's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

InVivo Therapeutics Holdings (FRA:04I) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

InVivo Therapeutics Holdings's Gross Margin % for the three months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

InVivo Therapeutics Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

InVivo Therapeutics Holdings (FRA:04I) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (FRA:04I) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

NVIV:USA

Address

One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139

Website

https://www.invivotherapeutics.com

InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

InVivo Therapeutics Holdings (FRA:04I) Headlines

No Headlines